Capricor Therapeutics, Inc. CAPR

Updated: 17 Jun 2026

NASDAQ | Biotech | Biotechnology and cell therapy

No signal published yet

We already track Capricor Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Capricor Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and cell therapy
We're already tracking Capricor Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On June 17, 2026, the company's stock rose significantly amid reports of a crucial hearing regarding its Duchenne muscular dystrophy therapy agreement. Earlier in the month, Capricor presented positive Phase 3 data for deramiocel and confirmed a PDUFA date of August 22, 2026.

What Firelda Watch includes for Capricor Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Capricor Therapeutics, Inc. will be delivered in the same format.

Want to follow Capricor Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Capricor Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Capricor Therapeutics, Inc. CAPR
Capricor Therapeutics — follow and we'll monitor it
Follow Capricor Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.